Changes of serum insulin-like growth factor-1 and growth hormone levels in patients with Graves' disease

Objective: To investigate the changes of serum insulin-like growth factor-1(IGF-1) and growth hormone (GH) levels in patients with Graves' disease (GD). Methods: The serum IGF-1 and GH levels were determined with RIA in 42 cases of GD, 20 cases of GD patients after therapy (in euthyroid state) and 30 normal controls. Results: The level of serum IGF-1 (170.8±44.4 ng/ml) and GH (2.80±1.18 ng/ml) were significantly higher in GD patients than those in controls [IGF-1 (90.5±30.5 ng/ml), GH(1.58±1.20 ng/ml)] (p<0.01, p<0.05). IGF-1 levels were positively correlated to FT4 levels (r=0.58, p<0.01). The levels of serum IGF-1 (110.4±33.2 ng/ml) and GH (1.71±1.36 ng/ml) after treatment were significantly lower than those before treatment (p<0.01, p<0.05). Conclusion: The levels of serum IGF-1 and GH were markedly increase in GD patients and might be influenced by changes of thyroid hormone levels